Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
Plasma prolactin (PRL) levels modifications after acute administration of L-dopa, L-dopa plus carbidopa and L-dopa plus benserazide were studied in parkinsonian patients. PRL increase after benserazide was compared with PRL response after carbidopa at the same dosage in untreated parkinsonian patients. A further study of the hyperprolactinemic effect of benserazide was performed in vitro on isolated and dispersed rat pituitary cells. The data gathered indicate that benserazide-induced hyperprolactinemia in parkinsonian patients could be due to a direct effect of the drug at the hypothalamic level and consequently to an inhibition of dopamine decarboxylation in the tuberoinfundibular dopaminergic system. It is not possible to exclude, however, that benserazide could exert its biological activity through the production of active metabolites in vivo.
D000368:Aged; D000818:Animals; D001545:Benserazide / Q000627:therapeutic use*; D002230:Carbidopa / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood*; D051381:Rats
D004338:Drug Combinations; D006834:Hydrazines; C005177:benserazide, levodopa drug combination; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D001545:Benserazide; D011388:Prolactin; D002230:Carbidopa